Centauri Therapeutics
Focus: Centauri Therapeutics is an early-stage UK-based biotech focused on Alphaprotein-based therapeutics, currently in Series A funding. The company operates at the discovery-to-early-clinical stage with a lean pipeline.
Profile data last refreshed 11h ago · AI intelligence enriched 2w ago
Funding Stage
SERIES A
Open Jobs
1
Should You Work at Centauri Therapeutics?
AI assessmentOnly pursue if you have deep technical conviction in the Alphamar platform and appetite for pre-revenue biotech risk; otherwise, career optionality is severely limited.
Why Work Here
- Ground-floor opportunity at a Series A biotech with novel Alphamer modality, offering potential for significant scientific impact and equity upside before later dilution rounds
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
DynaSense sensor
Pressure UlcersPlacebo
Bronchiectasis AdultClinical Trials (1)
Help build intelligence for Centauri Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.